[144] Disc Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 12,862 shares of common stock through Merrill Lynch One Bryant Park (New York) with an aggregate market value of $785,868.20. The filing states the company has 34,765,581 shares outstanding and lists the approximate sale date as 08/14/2025 on the Nasdaq.

The securities were originally acquired on 05/01/2020 in a private placement from the issuer, paid in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information. The notice includes the usual signature and legal attestation language.

Insights

Securities Analyst

TL;DR: Small insider/affiliate sale disclosed; size is immaterial relative to outstanding shares and unlikely to move the market.

The proposed sale of 12,862 shares equals roughly 0.037% of the reported 34,765,581 shares outstanding, indicating a modest disposition. The shares were acquired in a private placement on 05/01/2020 and are being sold through a major broker, which suggests a routine liquidity transaction rather than a strategic change. No prior three-month sales are reported, reducing concerns about staged divestment. From a market-impact perspective this notice is neutral.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 disclosure requirements and contains the standard seller attestation; no governance red flags visible.

The Form 144 provides required details: acquisition date, nature of acquisition (private placement from the issuer), payment method (cash), broker name, proposed sale date, and aggregate value. The attestation that the seller lacks undisclosed material adverse information is included. With no evidence of concurrent unusual activity or repeated recent sales, this filing appears compliant and routine from a governance standpoint.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch One Bryant Park New York NY 10036	12862	785868.20	34765581	08/14/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2020	Private Placement	Issuer			12862	05/01/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Disc Medicine's (IRON) Form 144 report?

The Form 144 reports a proposed sale of 12,862 common shares with an aggregate market value of $785,868.20, to be sold on 08/14/2025 via Merrill Lynch.

How many Disc Medicine shares are outstanding per the filing?

The filing lists 34,765,581 shares outstanding.

When and how were the shares being sold originally acquired?

The shares were acquired on 05/01/2020 in a private placement from the issuer and the purchase was paid in cash.

Were any Disc Medicine (IRON) securities sold in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale?

The proposed sale is to be executed through Merrill Lynch One Bryant Park, New York, NY.